TCT 2022 | Edge-to-Edge Repair in Patients with Severe Mitral Insufficiency and Cardiogenic Shock: Analysis of the TVT Registry

Approximately 1 in 5 patients admitted for cardiogenic shock (CS) were observed to have moderate to severe mitral insufficiency (MI), which increases the risk of mortality by about 60%. To date, there is limited data on the role of transcatheter edge-to-edge repair therapy in this setting.

TCT 2022

The aim of this study was to describe the risk profile, device success, and association between device implantation and events at 1 year. Data were obtained from 3797 patients; their mean age was 73±11 years; 59.9% of patients were men and the STS mortality risk was 14.9±15.3, with a mean ejection fraction of 41±17.5%.

In 47.8% of patients, there was more than 1 clip implanted. Complications observed included major bleeding (3.6%), life-threatening bleeding (4%), and stroke (1.6%), with an average hospitalization of 12.5 days.

Successful implantation was achieved in 85.6% of the cases. In patients who underwent successful implantation, there was a 51% decrease in mortality compared with failed implantation (hazard ratio [HR]: 0.49; 95% confidence interval [CI]: 0.41-0.59; p < 0.001), with a need-to-treat of 4.8. When analyzing the composite outcome of mortality/hospitalization for heart failure, the reduction was 49% (HR: 0.51; 95% CI: 0.42-0.62; p < 0.001).

Conclusions

The reduction of MI within CS is achievable in most patients and is associated with a decrease in mortality and hospitalizations at 1 year. Data come from registries and, therefore, only suggest a hypothesis to be addressed in the future.

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Font: Transcatheter Edge-to-Edge Repair in Patients with Severe Mitral Regurgitation and

Reference: Cardiogenic Shock: TVT Registry Analysis presentado por Mohamad A. Alkhouli, MD en TCT Congress, Boston, EE. UU. 17 septiembre de 2022.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....